At the recent American Society of Clinical Oncology (ASCO) annual meeting, interim results from the DESTINY-Breast09 trial ...

Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus ...

The HER2-specific tyrosine kinase inhibitor tucatinib, combined with trastuzumab and capecitabine, showed improved survival as compared with trastuzumab and capecitabine in patients with heavily ...

Trastuzumab deruxtecan (Enhertu; AstraZeneca/Daiichi Sankyo) in combination with pertuzumab (Perjeta; Genentech) demonstrated significantly longer progression-free survival (PFS) compared with the ...

SAN ANTONIO — Fam-trastuzumab deruxtecan-nxki significantly extended OS compared with ado-trastuzumab emtansine among previously treated patients with HER2-positive unresectable or metastatic ...

For the first time, a medicine aimed directly at the HER2 protein improved overall survival after gastric cancer progressed despite earlier trastuzumab-based therapy.

The Subject Expert Committee (SEC) on Oncology and Hematology, functioning under the Central Drugs Standard Control ...

Topline data were announced from a phase 3 trial evaluating fam-trastuzumab deruxtecan-nxki followed by THP in patients with high-risk, locally advanced HER2-positive early stage breast cancer.

WILMINGTON, Del., June 02, 2025--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...